EMC Capital Management Acquires 137 Shares of United Therapeutics Co. (NASDAQ:UTHR)

EMC Capital Management grew its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 9.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,577 shares of the biotechnology company’s stock after buying an additional 137 shares during the period. United Therapeutics makes up 0.3% of EMC Capital Management’s investment portfolio, making the stock its 29th largest holding. EMC Capital Management’s holdings in United Therapeutics were worth $556,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of UTHR. USA Financial Formulas acquired a new stake in United Therapeutics in the third quarter worth $33,000. Brooklyn Investment Group bought a new position in shares of United Therapeutics during the 3rd quarter worth about $33,000. Capital Performance Advisors LLP acquired a new stake in shares of United Therapeutics in the 3rd quarter valued at about $82,000. MassMutual Private Wealth & Trust FSB increased its position in United Therapeutics by 31.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 58 shares in the last quarter. Finally, Values First Advisors Inc. acquired a new position in United Therapeutics during the 3rd quarter worth approximately $90,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Activity at United Therapeutics

In other United Therapeutics news, Director Judy D. Olian sold 1,750 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $412.48, for a total transaction of $721,840.00. Following the completion of the transaction, the director now owns 5,655 shares in the company, valued at $2,332,574.40. This trade represents a 23.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Michael Benkowitz sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $370.71, for a total transaction of $3,707,100.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $955,319.67. This trade represents a 79.51 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 149,048 shares of company stock worth $56,142,199. 11.90% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on UTHR shares. The Goldman Sachs Group raised their price objective on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research note on Friday, November 1st. TD Cowen boosted their price target on shares of United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Argus upped their price objective on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. LADENBURG THALM/SH SH lifted their price objective on shares of United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Finally, StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 16th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $378.36.

United Therapeutics Stock Down 0.5 %

UTHR stock opened at $370.87 on Thursday. The firm has a market cap of $16.56 billion, a PE ratio of 16.29, a P/E/G ratio of 0.95 and a beta of 0.57. The business has a 50 day moving average of $365.77 and a 200-day moving average of $356.81. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $417.82.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. The firm had revenue of $748.90 million during the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business’s revenue for the quarter was up 22.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $5.38 EPS. On average, research analysts expect that United Therapeutics Co. will post 25.22 earnings per share for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.